Facio Therapies, founded in 2014 and based in Leiden, Netherlands, is solely focused on developing a causal therapy for FSHD by restoring natural repression of the muscle‑toxic DUX4 protein. Its core program centers on patient-derived cell screening and the discovery of small-molecule DUX4 repressors. Since 2015 Facio has collaborated with Evotec on high‑throughput drug discovery, with Evotec performing discovery work. Facio plans to use recent funding to accelerate its small‑molecule candidates toward selection of pre‑clinical lead compounds. The company emphasizes affordable, expedient development driven by leaders from the FSHD community. The clinical need is substantial: FSHD affects an estimated 700,000 people worldwide and currently has no approved disease‑modifying therapy.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2017